Crane Infrastructure Limited
Crane Infrastructure Limited (CRANEINFRA.BO) Stock Competitors & Peer Comparison
See (CRANEINFRA.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Residential Construction Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRANEINFRA.BO | ₹11.50 | +9.73% | 83.3M | 14.38 | ₹0.80 | N/A |
| BRRL.BO | ₹1,007.90 | +1.81% | 10.4B | 222.00 | ₹4.54 | N/A |
| COROENGG.BO | ₹94.50 | +2.00% | 3.3B | 115.24 | ₹0.82 | N/A |
| CHAVDA.NS | ₹89.00 | +9.47% | 2.2B | 10.40 | ₹8.56 | N/A |
| ALPINEHOU.BO | ₹85.16 | +12.88% | 1.5B | 25.73 | ₹3.31 | N/A |
| VAGHANI.BO | ₹233.40 | +0.00% | 1.2B | 243.13 | ₹0.96 | N/A |
| PRERINFRA.BO | ₹22.13 | +6.04% | 799.5M | 16.64 | ₹1.33 | N/A |
| GUJTLRM.BO | ₹0.47 | +9.30% | 654.4M | 0.47 | ₹0.99 | N/A |
| SHRISTI.BO | ₹28.00 | +2.75% | 621.6M | -4.96 | -₹5.65 | N/A |
| VARIMAN.BO | ₹2.88 | +4.73% | 560.4M | 20.57 | ₹0.14 | N/A |
Stock Comparison
CRANEINFRA.BO vs BRRL.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, BRRL.BO has a market cap of 10.4B. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while BRRL.BO trades at ₹1,007.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas BRRL.BO's P/E ratio is 222.00. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to BRRL.BO's ROE of +0.01%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to BRRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check BRRL.BO's competition here
CRANEINFRA.BO vs COROENGG.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, COROENGG.BO has a market cap of 3.3B. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while COROENGG.BO trades at ₹94.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas COROENGG.BO's P/E ratio is 115.24. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to COROENGG.BO's ROE of +0.26%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to COROENGG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check COROENGG.BO's competition here
CRANEINFRA.BO vs CHAVDA.NS Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, CHAVDA.NS has a market cap of 2.2B. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while CHAVDA.NS trades at ₹89.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas CHAVDA.NS's P/E ratio is 10.40. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to CHAVDA.NS's ROE of N/A. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to CHAVDA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check CHAVDA.NS's competition here
CRANEINFRA.BO vs ALPINEHOU.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, ALPINEHOU.BO has a market cap of 1.5B. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while ALPINEHOU.BO trades at ₹85.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas ALPINEHOU.BO's P/E ratio is 25.73. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to ALPINEHOU.BO's ROE of +0.07%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to ALPINEHOU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check ALPINEHOU.BO's competition here
CRANEINFRA.BO vs VAGHANI.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, VAGHANI.BO has a market cap of 1.2B. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while VAGHANI.BO trades at ₹233.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas VAGHANI.BO's P/E ratio is 243.13. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to VAGHANI.BO's ROE of +0.03%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to VAGHANI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check VAGHANI.BO's competition here
CRANEINFRA.BO vs PRERINFRA.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, PRERINFRA.BO has a market cap of 799.5M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while PRERINFRA.BO trades at ₹22.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas PRERINFRA.BO's P/E ratio is 16.64. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to PRERINFRA.BO's ROE of +0.02%. Regarding short-term risk, CRANEINFRA.BO is less volatile compared to PRERINFRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check PRERINFRA.BO's competition here
CRANEINFRA.BO vs GUJTLRM.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, GUJTLRM.BO has a market cap of 654.4M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while GUJTLRM.BO trades at ₹0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas GUJTLRM.BO's P/E ratio is 0.47. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to GUJTLRM.BO's ROE of +0.04%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to GUJTLRM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check GUJTLRM.BO's competition here
CRANEINFRA.BO vs SHRISTI.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, SHRISTI.BO has a market cap of 621.6M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while SHRISTI.BO trades at ₹28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas SHRISTI.BO's P/E ratio is -4.96. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to SHRISTI.BO's ROE of +0.09%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to SHRISTI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check SHRISTI.BO's competition here
CRANEINFRA.BO vs VARIMAN.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, VARIMAN.BO has a market cap of 560.4M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while VARIMAN.BO trades at ₹2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas VARIMAN.BO's P/E ratio is 20.57. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to VARIMAN.BO's ROE of +0.06%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to VARIMAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check VARIMAN.BO's competition here
CRANEINFRA.BO vs MANJEERA.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, MANJEERA.BO has a market cap of 450.3M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while MANJEERA.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas MANJEERA.BO's P/E ratio is 1.96. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to MANJEERA.BO's ROE of -0.01%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to MANJEERA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check MANJEERA.BO's competition here
CRANEINFRA.BO vs SISL.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, SISL.BO has a market cap of 377M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while SISL.BO trades at ₹209.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas SISL.BO's P/E ratio is 7.44. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to SISL.BO's ROE of +0.43%. Regarding short-term risk, CRANEINFRA.BO is less volatile compared to SISL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check SISL.BO's competition here
CRANEINFRA.BO vs PARSHWANA.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, PARSHWANA.BO has a market cap of 305.8M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while PARSHWANA.BO trades at ₹97.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas PARSHWANA.BO's P/E ratio is 91.26. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to PARSHWANA.BO's ROE of +0.03%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to PARSHWANA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check PARSHWANA.BO's competition here
CRANEINFRA.BO vs POPULARES.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, POPULARES.BO has a market cap of 187.3M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while POPULARES.BO trades at ₹13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas POPULARES.BO's P/E ratio is -1338.00. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to POPULARES.BO's ROE of -0.00%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to POPULARES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check POPULARES.BO's competition here
CRANEINFRA.BO vs ADHBHUTIN.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, ADHBHUTIN.BO has a market cap of 146.1M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while ADHBHUTIN.BO trades at ₹13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas ADHBHUTIN.BO's P/E ratio is -11.75. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to ADHBHUTIN.BO's ROE of +0.19%. Regarding short-term risk, CRANEINFRA.BO is less volatile compared to ADHBHUTIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check ADHBHUTIN.BO's competition here
CRANEINFRA.BO vs DRL.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, DRL.BO has a market cap of 144.5M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while DRL.BO trades at ₹19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas DRL.BO's P/E ratio is -123.44. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to DRL.BO's ROE of -0.00%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to DRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check DRL.BO's competition here
CRANEINFRA.BO vs LAHL.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, LAHL.BO has a market cap of 119.7M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while LAHL.BO trades at ₹6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas LAHL.BO's P/E ratio is -72.67. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to LAHL.BO's ROE of -0.01%. Regarding short-term risk, CRANEINFRA.BO is less volatile compared to LAHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check LAHL.BO's competition here
CRANEINFRA.BO vs QUANTBUILD.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, QUANTBUILD.BO has a market cap of 119.6M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while QUANTBUILD.BO trades at ₹4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas QUANTBUILD.BO's P/E ratio is -36.69. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to QUANTBUILD.BO's ROE of -0.05%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to QUANTBUILD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check QUANTBUILD.BO's competition here
CRANEINFRA.BO vs CEMAINFRA.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, CEMAINFRA.BO has a market cap of 119.1M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while CEMAINFRA.BO trades at ₹4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas CEMAINFRA.BO's P/E ratio is -36.54. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to CEMAINFRA.BO's ROE of -0.05%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to CEMAINFRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check CEMAINFRA.BO's competition here
CRANEINFRA.BO vs SKIFL.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, SKIFL.BO has a market cap of 104.5M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while SKIFL.BO trades at ₹9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas SKIFL.BO's P/E ratio is -9.69. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to SKIFL.BO's ROE of +0.00%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to SKIFL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check SKIFL.BO's competition here
CRANEINFRA.BO vs KMFBLDR.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, KMFBLDR.BO has a market cap of 88.3M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while KMFBLDR.BO trades at ₹7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas KMFBLDR.BO's P/E ratio is 9.06. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to KMFBLDR.BO's ROE of +0.08%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to KMFBLDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check KMFBLDR.BO's competition here
CRANEINFRA.BO vs EASTBUILD.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, EASTBUILD.BO has a market cap of 87.4M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while EASTBUILD.BO trades at ₹46.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas EASTBUILD.BO's P/E ratio is -7.21. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to EASTBUILD.BO's ROE of -0.18%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to EASTBUILD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check EASTBUILD.BO's competition here
CRANEINFRA.BO vs NYSSACORP.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, NYSSACORP.BO has a market cap of 67.8M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while NYSSACORP.BO trades at ₹2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas NYSSACORP.BO's P/E ratio is -3.77. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to NYSSACORP.BO's ROE of -0.06%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to NYSSACORP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check NYSSACORP.BO's competition here
CRANEINFRA.BO vs MAHESH.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, MAHESH.BO has a market cap of 51.1M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while MAHESH.BO trades at ₹12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas MAHESH.BO's P/E ratio is -87.86. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to MAHESH.BO's ROE of +0.03%. Regarding short-term risk, CRANEINFRA.BO is less volatile compared to MAHESH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check MAHESH.BO's competition here
CRANEINFRA.BO vs UNISHIRE.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, UNISHIRE.BO has a market cap of 30.9M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while UNISHIRE.BO trades at ₹1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas UNISHIRE.BO's P/E ratio is -4.70. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to UNISHIRE.BO's ROE of -0.01%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to UNISHIRE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check UNISHIRE.BO's competition here
CRANEINFRA.BO vs ATHCON.BO Comparison April 2026
CRANEINFRA.BO plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRANEINFRA.BO stands at 83.3M. In comparison, ATHCON.BO has a market cap of 26.4M. Regarding current trading prices, CRANEINFRA.BO is priced at ₹11.50, while ATHCON.BO trades at ₹3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRANEINFRA.BO currently has a P/E ratio of 14.38, whereas ATHCON.BO's P/E ratio is -3.45. In terms of profitability, CRANEINFRA.BO's ROE is +0.02%, compared to ATHCON.BO's ROE of -0.12%. Regarding short-term risk, CRANEINFRA.BO is more volatile compared to ATHCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CRANEINFRA.BO.Check ATHCON.BO's competition here